Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

Terumo receives CE Mark for Ultimaster TANSEI drug-eluting stenthttps://www.terumo-europe.com/en-emea/news/terumo-receives-ce-mark-for-ultimaster-tansei-drug-eluting-stentTerumo receives CE Mark for Ultimaster TANSEI drug-eluting stentLeuven, Belgium22/04/2018 22:00:00<p><font size="3">Granting of ‘Conformité Européenne’ a major milestone as Terumo gears up for global launches of next generation drug-eluting stent (DES) </font></p>
Terumo and Quirem welcome the positive reimbursement decision for QuiremSpheres® in the Netherlandshttps://www.terumo-europe.com/en-emea/news/terumo-and-quirem-welcome-the-positive-reimbursement-decision-for-quiremspheres®-in-the-netherlandsTerumo and Quirem welcome the positive reimbursement decision for QuiremSpheres® in the NetherlandsLeuven, Belgium11/04/2018 22:00:00<p style="text-align:justify;">​Terumo and Quirem welcome an important milestone for QuiremSpheres® in the Netherlands and in Europe. QuiremSpheres® is now reimbursed for liver-dominant, non-resectable, colorectal liver metastases in the salvage setting<sup>1</sup>, as concluded by the Dutch National Healthcare Institute ('Zorginstituut'). The treatment consists of the injection of holmium-microspheres in the main liver artery with the purpose of destroying the cancer cells and is referred to as radioembolization or selective internal radiation therapy (SIRT). The National Healthcare Institute concludes that this innovative treatment with holmium-166 microspheres, which has been developed in the Netherlands, meets "established medical science and medical practice"<sup>2</sup> for this indication.</p>
Terumo Acquires Large Bore Vascular Closure Device to Expand Its Interventional Access Device Business in the Fast Growing Segmenthttps://www.terumo-europe.com/en-emea/news/terumo-acquires-large-bore-vascular-closure-device-to-expand-its-interventional-access-device-business-in-the-fast-growingTerumo Acquires Large Bore Vascular Closure Device to Expand Its Interventional Access Device Business in the Fast Growing SegmentTokyo, Japan01/03/2018 23:00:00<p style="text-align:justify;">​<font size="3">Terumo Corporation (TSE: 4543) today announced that it has entered into an agreement to acquire assets related to the large bore vascular closure device from Medeon Biodesign, Inc., a Taiwanese publicly traded medical device company. Under the terms of the agreement, Terumo will pay US$20 million upfront and additional payments based on the achievement of future specific development milestones. It will be funded through cash on hand. The impact of the acquisition on Terumo’s business performance is being examined. </font></p>
Terumo Pharmaceutical Solutions wins Asia-Pacific Industry Awardhttps://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-wins-asia-pacific-industry-awardTerumo Pharmaceutical Solutions wins Asia-Pacific Industry AwardTOKYO, JAPAN and LEUVEN, BELGIUM25/02/2018 23:00:00<p style="text-align:justify;"><span aria-hidden="true"></span><span aria-hidden="true"></span>January 31<sup><font size="2">st</font></sup>, 2018 – Tokyo-based Terumo Corporation (TSE: 4543) has today announced  that Terumo Pharmaceutical Solutions<strong> </strong> has been awarded the Asia-Pacific Bioprocessing Excellence Award 2018 on January 31<sup><font size="2">st</font></sup> at the 5<sup><font size="2">th</font></sup> Biologics Manufacturing Asia & 2nd Biologistics World Asia 2018 conference awards night held in Singapore.</p><p style="text-align:justify;">Terumo Pharmaceutical Solutions was nominated in the category, 'Best Bioprocessing Supplier Award: Formulation & Fill-Finish' and competed with several other established companies in the industry. </p><p style="text-align:justify;">Hideo Arase, Director and Senior Executive Officer, Terumo Corporation, Managing Director, Terumo Asia Holdings and Ashit Sikka, Director, Terumo Pharmaceutical Solutions, India accepted this award on the night on behalf of Terumo. </p>
Approval of LifePearl® Microspheres as a Class III device in Europehttps://www.terumo-europe.com/en-emea/news/approval-of-lifepearl®-microspheres-as-a-class-iii-device-in-europeApproval of LifePearl® Microspheres as a Class III device in EuropeLeuven, Belgium18/01/2018 23:00:00<p>Terumo Europe N.V, announces the approval of LifePearl Microspheres as a Class III device in Europe.  This approval also expands the loadable chemotherapeutic drugs to include Idarubicin and Epirubicin.</p>